1. Home
  2. VSTS vs PGEN Comparison

VSTS vs PGEN Comparison

Compare VSTS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vestis Corporation

VSTS

Vestis Corporation

HOLD

Current Price

$12.88

Market Cap

1.6B

Sector

N/A

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.20

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTS
PGEN
Founded
1936
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
VSTS
PGEN
Price
$12.88
$4.20
Analyst Decision
Sell
Buy
Analyst Count
4
5
Target Price
$5.88
$8.33
AVG Volume (30 Days)
2.0M
3.6M
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,734,839,000.00
$230,981,000.00
Revenue This Year
N/A
$1,115.92
Revenue Next Year
$1.67
$81.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$1.28
52 Week High
$12.93
$5.47

Technical Indicators

Market Signals
Indicator
VSTS
PGEN
Relative Strength Index (RSI) 70.40 50.25
Support Level $6.81 $3.96
Resistance Level N/A $4.40
Average True Range (ATR) 0.72 0.27
MACD 0.07 -0.01
Stochastic Oscillator 95.80 29.89

Price Performance

Historical Comparison
VSTS
PGEN

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: